Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260743 | 1.00 | NLRP3 (0.36) | NLRP3PDK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL27921332 | 0.86 | ALDH1A1 (0.40) | NLRP3ALDH1A1TSHR | |
| SCHEMBL1871684 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL11207152 | 0.83 | CHRM5 (0.35) | ALDH1A1TSHR | |
| SCHEMBL11640528 | 0.83 | LMNA (0.34) | ALDH1A1LMNA | |
| SCHEMBL11637868 | 0.83 | POLB (0.32) | ALDH1A1TSHR | |
| SCHEMBL8428847 | 0.83 | ALDH1A1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL18570723 | 0.80 | LMNA (0.51) | ALDH1A1LMNA | |
| SCHEMBL4304520 | 0.80 | TP53 (0.37) | TP53CYP3A4LMNA | |
| SCHEMBL8429838 | 0.80 | LMNA (0.47) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129274-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023141536-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS | ABBVIE INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2006-06-15 | — | — | US | disclosed |
| WO-2006034190-A2 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0039060-B1 | A NEW METHOD FOR PREPARATION OF ANTHRACYCLINE DERIVATIVES | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1986-08-06 | — | — | EP | disclosed |
| EP-0014853-B1 | ANTHRACYCLINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1983-06-01 | — | — | EP | disclosed |
| US-4360664-A | ANTITUMOR AGENT, ANTIBIOTIC | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-11-23 | — | — | US | disclosed |
| US-4303785-A | ETHERS OF ADRIAMYCIN AND DAUNORUBICIN | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1981-12-01 | — | — | US | disclosed |
| EP-0039060-A1 | A new method for preparation of anthracycline derivatives | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1981-11-04 | — | — | EP | disclosed |
| EP-0039060-A1 | A new method for preparation of anthracycline derivatives | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1981-11-04 | — | — | EP | disclosed |
| EP-0014853-A1 | Anthracycline derivatives, a process for their preparation and pharmaceutical compositions containing them | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1980-09-03 | — | — | EP | disclosed |
| US-4107289-A | Use of substituted pyrans as deodorant chemicals | NAARDEN INTERNATIONAL HOLLAND, B.V. (NL) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673907-B2 | Modular synthesis of aminoglycosides | MRPL21, COASY, AARS1 | NLRP3 3617/4885PDK1 1104/4885ALDH1A1 4379/4885 |
| US-12129274-B2 | Modular synthesis of aminoglycosides | MRPL21, COASY, AARS1 | NLRP3 3617/4885PDK1 1104/4885ALDH1A1 4379/4885 |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | NLRP3 716/4885PDK1 1226/4885ALDH1A1 3975/4885 |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | NLRP3 3617/4885PDK1 1104/4885ALDH1A1 4379/4885 |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | BCL9L, BCL2L1, BCL2L2 | NLRP3 3820/4885PDK1 1620/4885ALDH1A1 912/4885 |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | BCL9L, BCL2L1, BCL9 | NLRP3 3844/4885PDK1 1644/4885ALDH1A1 920/4885 |
| US-20060128652-A1 | Purine derivatives and methods of use thereof | PNP, NUDT1, HPRT1 | NLRP3 61/4885PDK1 340/4885ALDH1A1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.